N/A N=250 Communication and Activation in Pain to Enhance Relationships and Treat Pain With Equity
Pain
Primary: Patient Activation — 60.39; 57.58 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Gastric Adenocarcinoma · Esophageal Adenocarcinoma · Metastasis
Primary: Best Objective Response Rate (bORR) — 61; 50 Percentage of participants
N/A N=322 Prevention of Substance Use in At-Risk Students: A Family-Centered Web Program
Substance Use · Conduct Disorders in Adolescence · Depression
Primary: Change From Baseline in Youth Effortful Control Across 12 Months (Parent Report) — 3.37; 3.19; 3.34; 3.39 score on a scale — p=.549
Phase 2 N=15 Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD
Peripheral Artery Disease
Primary: Number of Participants With Aneurysm Formation, Anastomotic Bleeding or Spontaneous Rupture, HAV Infection, HAV Removal, and Significant Inflammation at the HAV…
Phase 2 N=49 Impact of Nicotine Reduction on Adolescent Cigarette Use, Alternative Tobacco Use, and Harm From Tobacco
Nicotine Dependence, Cigarettes, Uncomplicated
Primary: Average Cigarettes Smoked Per Day — 4.3; 8.0 average cigarettes per day — p=.111
Phase 2 N=15 An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.
Submental Fat
Primary: Pharmacokinetics Measure - Drug Concentration in the Blood (ng/mL) — 487.7; 473.3 concentration (ng/ml)
N/A N=37 Bright Light Treatment At Home To Manage Chronic Pain In U.S. Veterans
Chronic Low Back Pain
Primary: Patient Reported Outcomes Measurement Information System Pain Intensity — 48.84 units on a scale — p=0.05
Phase 2 N=148 Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma · Combined Hepatocellular and Cholangiocarcinoma
Primary: Substudy 1: Objective Response Rate (ORR) — 22.3 Percentage of participants
N/A N=94 CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management
Type 1 Diabetes Mellitus
Primary: Family Communication Inventory Questionnaire — 12.3; 11.5 Score on a scale — p=>0.05
Phase 3 N=14 Neuroprotection in Acute Ischemic Stroke
Stroke, Ischemic
Primary: Number of Participants With Favorable Outcome on the Simplified Modified Rankin Scale (sMRSq) — 5; 7; 1; 1 participants
N/A N=29 Behavioral Activation and Medication Optimization for Perioperative Mental Health Feasibility Study
Older Adults · Anxiety · Depression
Primary: Reach of the Study as Measured by the Number of Participants Who Agree to Participate in the Study Out of the Total Eligible Participants — 23 Participants
Phase 2 N=84 Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)
Heart Failure
Primary: Difference in Peak Oxygen Consumption (Vo2) Between KNO3 and KCl Phases — 10.31714; 10.215172 L/min/kg — p=0.6191
N/A N=20 Stanford Tobacco Treatment Services - Virtual Reality Treatment for Smoking Cessation
Smoking Cessation · MindCotine Virtual Reality Mindful Exposure Therapy
Primary: Number of Patients Who Registered With the MindCotine Application — 9 Participants
N/A N=100 Impact of More Frequent PT Services
Mobility Limitation · Physical Disability · Stroke, Acute
Primary: Change in Score of Postural Assessment Stroke Scale (PASS) — 10.23; 5.78 score on a scale
N/A N=29 Effect of High Carbohydrate vs. Low Carbohydrate Diet in Type 2 Diabetes
Diabetes Mellitus · Diabetes Mellitus, Type 2
Primary: Hepatic Glycogen Content and Rates of Gluconeogenesis in Subjects With Type 2 Diabetes — 8.2; 9.4; 17.4; 15.6 umol/kgFFM/min